help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, M. C.
Right arrow Articles by Jaffe, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, M. C.
Right arrow Articles by Jaffe, R. B.

Journal of Clinical Endocrinology & Metabolism, Vol 59, 485-490, Copyright © 1984 by Endocrine Society

ARTICLES

Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion

MC Martin, RI Weiner, SE Monroe, JM Roberts, V Licko and RB Jaffe

Previous studies demonstrated that high doses of dopamine administered as a constant infusion were capable of suppressing PRL secretion in both normal and hyperprolactinemic individuals. The present study was designed to examine the dose-response relationship of PRL suppression to low doses of dopamine (between 0.06 and 4 micrograms/kg X min) infused in a step-wise fashion. Ten hyperprolactinemic patients with PRL-secreting pituitary adenomas and 10 normally menstruating women in the early follicular phase of a cycle were studied. For hyperprolactinemic women, the mean (+/- SD) serum PRL level (by RIA) was 112 +/- 101 ng/ml, with a range of 26-386 ng/ml, the mean estradiol level (by RIA) was 28 +/- 8 pg/ml, and the mean baseline dopamine level by carboxy-o-methyl transferase assay (COMT) was 357 +/- 237 pg/ml (2.33 +/- 1.54 X 10(-9) M). The normal women had a mean PRL of 8.1 +/- 3.5 ng/ml, a mean estradiol level of 42 +/- 12 pg/ml, and a mean baseline dopamine level of 317 +/- 223 pg/ml (2.07 +/- 1.45 X 10(-9) M). Concentrations of dopamine achieved at the lowest doses infused were less than 10 times baseline levels and were in the nanomolar range. The measured IC50 (the concentration of dopamine required to achieve 50% of maximal suppression) was 6 +/- 3 X 10(-9) M for normal women and 14 +/- 4 X 10(-9) M for hyperprolactinemic patients. The apparent inhibition constant determined by a nonlinear least squares procedure, was 3 +/- 3 X 10(-9) M for normal women and 11 +/- 12 X 10(- 9) M for women with hyperprolactinemia. Both groups exhibited dose- dependent suppression of PRL to about 80% of initial values. Under these experimental conditions, the data do not support the hypothesis that there is a marked loss in sensitivity to dopamine in patients with PRL-secreting adenomas.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society